Julio Gagne has worked in drug development for over 20 years in a variety of capacities from bench science to program & portfolio management. He has focused on oncology in the second half of his career at companies including Onyx Pharmaceuticals, Novartis Oncology, Bristol Myers and currently at ImmunoGen Inc. working on such drugs as Nexavar, Exjade, Yervoy and nivolumumab.